Daniel Engber

Daniel Engber is a journalist and author who has written extensively on health topics including weight loss drugs. He has also covered other areas such as politics and science.

Biography:  https://www.theatlantic.com/author/daniel-engber/

58%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author has a mixed reputation for journalistic standards. It is advisable to fact-check, scrutinize for bias, and check for conflicts of interest before relying on the author's reporting.

Bias

85%

Examples:

  • The program, called Shame, Blame and the Weight Loss Revolution,

Conflicts of Interest

50%

Examples:

  • The article mentions a program called Shame, Blame and the Weight Loss Revolution which may have been influenced by financial interests.
  • There are no clear indications of any conflicts of interest in this article.

Contradictions

100%

Examples:

  • The article mentions Oprah's special on Shame, Blame and the Weight Loss Revolution where she only talks about GLP-1 receptor agonists. However, this is not true as there were other medications available before Ozempic and Wegovy which have been used to treat obesity for years.
  • The article mentions that patients and physicians alike have forgotten the existence of these almost-as-effective ones, they will not receive another mention. This implies that GLP-1 receptor agonists are the only medications available for obesity when this is not true.

Deceptions

30%

Examples:

  • The article mentions Oprah's special on Shame, Blame and the Weight Loss Revolution where she only talks about GLP-1 receptor agonists. However, this is not true as there were other medications available before Ozempic and Wegovy which have been used to treat obesity for years.
  • The article mentions that patients and physicians alike have forgotten the existence of these almost-as-effective ones, they will not receive another mention. This implies that GLP-1 receptor agonists are the only medications available for obesity when this is not true.

Recent Articles

The Dangers of Weight Loss Drugs: Ozempic and Mounjaro Lawsuits Highlight Side Effects Risk

The Dangers of Weight Loss Drugs: Ozempic and Mounjaro Lawsuits Highlight Side Effects Risk

Broke On: Sunday, 31 March 2024 Weight loss drugs Ozempic and Mounjaro have been linked to harsh side effects, including intestinal blockage, nausea, vomiting and abdominal pain. The FDA has placed a warning on their labels about these risks. However, these medications don't address the root causes of weight gain. It is important to consult with a healthcare professional before starting any new medication or diet plan.